-
Jul 30, 2024 | 
jamanetwork.com | william wang |Nora D. Volkow |Nathan A Berger |Pamela Davis
Introduction Drug overdose fatalities in the United States remain high, with an estimated 107 543 deaths in 2023, mostly from opioids.1 Despite the effectiveness of medications for opioid use disorder (OUD) in preventing overdoses, only an estimated 25% of individuals with OUD receive them,2 and close to 50% discontinue treatment within 6 months. There is an urgency for alternative treatments for OUD.
-
Jun 18, 2024 | 
nature.com | Nora D. Volkow |Nathan A Berger |Pamela Davis |David C. Kaelber
Correction to: Nature Communications https://doi.org/10.1038/s41467-024-48780-6, published online 28 May 2024In this article in the abstract the word clinical was misspelt as clinicl.
-
Jun 11, 2024 | 
bottomlineinc.com | Nathan A Berger
The new weight loss drugs are called glucagon-like peptide-1 receptor agonists (GLP-1RA). The first drug, exenatide (Byetta), was approved to treat type 2 diabetes (T2D) in 2005. It was a breakthrough for people with T2D, but not a media attention grabber. As researchers continued to develop new GLP-1RA drugs, and as people started using them more, it became apparent that people on the drugs were losing weight.
-
May 27, 2024 | 
nature.com | Nora D. Volkow |Nathan A Berger |Pamela Davis |David C. Kaelber
AbstractAlcohol use disorders are among the top causes of the global burden of disease, yet therapeutic interventions are limited. Reduced desire to drink in patients treated with semaglutide has raised interest regarding its potential therapeutic benefits for alcohol use disorders.
-
Apr 13, 2024 | 
nyyrc.com | Nathan A Berger
Recent attacks on President Donald J. Trump by activist prosecutors have shown that the enforcement of criminal and civil law has been totally politicized. No longer do statute and precedent guide prosecutorial discretion; in a world where Letitia James, Alvin Bragg, and Fani Willis hold power, every American must recognize that his government might defy tradition to pursue him in novel ways.
-
Mar 14, 2024 | 
jamanetwork.com | Lindsey Wang |Rong Xu |David C. Kaelber |Nathan A Berger
Key PointsQuestion Is there clinical evidence supporting the potential benefits of glucagon-like peptide receptor agonists (GLP-1RAs) for the prevention of 13 obesity-associated cancers (OACs)?
-
Jan 21, 2024 | 
nyyrc.com | Nathan A Berger
On Sunday afternoon, Florida governor Ron DeSantis suspended his pitiful and futile presidential campaign and endorsed President Donald J. Trump. Once viewed as a respectable and skillful politician, DeSantis has thoroughly embarrassed himself with his contemptible disloyalty toward the former president. It ought not be forgotten that Trump saved DeSantis’s fledgling gubernatorial campaign in 2018.
-
Jan 5, 2024 | 
nature.com | Nora D. Volkow |Nathan A Berger |Pamela Davis |David C. Kaelber
AbstractConcerns over reports of suicidal ideation associated with semaglutide treatment, a glucagon-like peptide 1 receptor (GLP1R) agonist medication for type 2 diabetes (T2DM) and obesity, has led to investigations by European regulatory agencies. In this retrospective cohort study of electronic health records from the TriNetX Analytics Network, we aimed to assess the associations of semaglutide with suicidal ideation compared to non-GLP1R agonist anti-obesity or anti-diabetes medications.
-
Dec 27, 2023 | 
youhavetoliveyour.life | Hayley Gleeson |Lindsey Wang |Pamela Davis |Nathan A Berger
Australian Broadcasting Corporation Other / Mixed Journalist Study Other / Mixed Article on a study Journalist Article on a study Journalist Other / Mixed Group of professionals Study Other / Mixed Johns Hopkins Bloomberg School of Public Health Other / Mixed Other / Mixed University of Auckland News and Opinion Article on a study Other / Professional Article on a study Other / Mixed...
-
Dec 7, 2023 | 
jamanetwork.com | Lindsey Wang |william wang |David C. Kaelber |Nathan A Berger
GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are approved by the US Food and Drug Administration for treating type 2 diabetes (T2D).
